Forma Therapeutics Holdings, Inc. (FMTX)


0.00 (-%)
Symbol FMTX
Price $20.01
Beta -0.948
Volume Avg. 1.47M
Market Cap 1.008B
Shares () -
52 Week Range 4.95-20.68
1y Target Est -
DCF Unlevered FMTX DCF ->
DCF Levered FMTX LDCF ->
ROE -39.68% Strong Sell
ROA -40.02% Strong Sell
Operating Margin -
Debt / Equity 14.64% Neutral
P/E -
P/B -


Consensus EPS

Upgrades & Downgrades

Latest FMTX news

Mr. Frank D. Lee
NASDAQ Global Market

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.